Second-line systemic therapy for the treatment of metastatic renal cell cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line systemic therapy for the treatment of metastatic renal cell cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 12, Issue 6, Pages 777-785
Publisher
Informa UK Limited
Online
2012-08-03
DOI
10.1586/era.12.43
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
- (2011) J. Beck et al. ANNALS OF ONCOLOGY
- Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
- (2011) Camillo Porta et al. BJU INTERNATIONAL
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
- (2011) Jean-Jacques Patard et al. EUROPEAN UROLOGY
- Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
- (2011) James Larkin et al. Expert Review of Anticancer Therapy
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
- (2011) E. Herrmann et al. WORLD JOURNAL OF UROLOGY
- Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
- (2010) Jorge A. Garcia et al. CANCER
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
- (2010) Walter M. Stadler et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
- (2010) Börje Ljungberg et al. EUROPEAN UROLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Nierenzellkarzinom
- (2010) J. Bedke et al. UROLOGE
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
- (2009) M.P. Sablin et al. JOURNAL OF UROLOGY
- Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
- (2008) Arkadiusz Z. Dudek et al. CANCER
- Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
- (2008) Christian Eichelberg et al. EUROPEAN UROLOGY
- Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence
- (2008) Joaquim Bellmunt EUROPEAN UROLOGY SUPPLEMENTS
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells
- (2008) Harriet M Kluger et al. LABORATORY INVESTIGATION
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation